About
Precision medicine is changing the way physicians approach prostate cancer care, incorporating information about a patient’s inherited genetic makeup and that of their prostate cancer in order to formulate individualized treatment plans. Cutting-edge advances in underlying prostate cancer biology and genetics are shaping treatment and guiding the development of new therapeutics and clinical trials. Get the latest information straight from the experts!
When
Thu, Jul 15, 2021 · 7:00 PM EDT
WEBINAR ENDED
Presenters
1624372222-613150ea3a3dadc0
Maria Carlo, MD
Dr. Maria Isabel Carlo is medical oncologist in the Genitourinary Oncology and Clinical Genetics services at Memorial Sloan Kettering Cancer Center. Her research interests are in understanding the role of inherited genetics in the development and treatment of cancer, especially prostate, bladder and kidney cancer.
1624372063-0e0e5e441382e1fc
Christopher Barbieri, MD, PhD
Dr. Christopher Barbieri is a urologic oncologist whose research interests include using genomic data to define distinct molecular subclasses of urologic malignancy, with a particular focus on prostate cancer. His work has led to recognition as a Prostate Cancer Foundation Young Investigator and a Urology Care Foundation Research Scholar; he is also the recipient of a Career Development Award from the National Cancer Institute to fund his work on prostate cancer. In addition, Dr. Barbieri has also been recognized as a Rising Star in Urology Research by the American Urological Association, and with a Clinical Investigator Award from the Damon Runyon Cancer Research Foundation.
1623767320-4f3ae979680da7a9
David Nanus, MD
Dr. David Nanus is an internationally recognized leader in the treatment and care of patients with genitourinary (GU) cancers, including cancers of the prostate, kidney, bladder and testes. He is actively involved in clinical, translational and basic research in GU malignancies, serving as principle or co-investigator on a variety of clinical research trials that incorporate novel targeted therapies for his patients. Dr. Nanus is Director of the NewYork-Presbyterian and Weill Cornell Medicine Healthcare Services Cancer Program, a program unifying oncology and hematology clinical care and research at NewYork-Presbyterian’s regional hospitals. He previously served as Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian.
1623767343-594ea844644af9bd
Susan Slovin, MD, PhD
Dr. Susan Slovin is an Attending Physician in the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center and a Professor of Medicine at Weill Cornell Medical College. She is a board-certified medical oncologist with expertise in the areas of prostate cancer immunology and clinical trial design. A noted immunologist, she leads an initiative that focuses on the development of novel immunologic approaches for the treatment of prostate cancer. This includes assuming leadership of the Prostate Immunotherapy Group, sponsored by the Prostate Cancer Foundation, whose challenge is to develop guidelines for development of immune therapy clinical trials in prostate cancer.
1623767335-656f9c5e86f04b5c
Mark Stein, MD
Dr. Mark Stein is an Associate Professor of Medical Oncology at Columbia University Medical Center. He is a recognized expert in the field of genitourinary oncology, treating patients with prostate, kidney, bladder and testicular cancers. In addition to providing standard therapies for the treatment of genitourinary cancers, such as hormonal therapy, molecularly targeted therapy and chemotherapy, Dr. Stein leads multiple investigator-initiated and industry-sponsored clinical trials. He has a particular interest in the development of novel immune therapies for the treatment of prostate cancer, both in men with early recurrence of prostate cancer, as well as in men with advanced prostate cancer.
Register To Watch Recording
Full name*
Email Address*
We use BigMarker as our webinar platform. By clicking Register, you acknowledge that the information you provide will be transferred to BigMarker processing in accordance with their Terms of Service and Privacy Policy.